Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary Microdose Array Print (MAP™) platform technology.
Employees: 51-200
Total raised: $15M
Founded date: 2014
Funding Rounds 1
| Date | Series | Amount | Investors |
| 29.11.2022 | - | $15M | - |
Mentions in press and media 12
| Date | Title | Description |
| 27.09.2024 | Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering | NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company with two FDA-approved products and a late-stage asset in development for the treatment of pediatric p... |
| 21.08.2024 | Eyenovia Announces Pricing of $5.14 Million Public Offering | NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has agreed to sell 12,850,000 shares of common stock at a price per shar... |
| 07.08.2024 | Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States | TAIPEI, Aug. 7, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has signed a non-binding terms agreement with Eyenovia, Inc. ("Eyenovia", NASDAQ: EYEN), wh... |
| 07.08.2024 | Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States | TAIPEI, Aug. 7, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has signed a non-binding terms agreement with Eyenovia, Inc. ("Eyenovia", NASDAQ: EYEN), wh... |
| 28.06.2024 | Eyenovia Announces Pricing of $5M Registered Direct Offering | NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has entered into a securities purchase agreement with an institutional i... |
| 28.06.2024 | Eyenovia Announces Pricing of $5M Registered Direct Offering | NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has entered into a securities purchase agreement with an institutional i... |
| 13.03.2024 | NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals | - |
| 05.03.2024 | Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery | - |
| 29.11.2022 | Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund | - |
| 29.11.2022 | Eyenovia Secures $15M for Ophthalmic Drug Delivery Technologies | What You Should Know: Eyenovia is developing a pipeline of advanced therapeutics based on its proprietary Microdose Array Print (MAP™) platform technology. Eyenovia aims to achieve clinical microdosing of next-generation formulations of wel... |
Show more